MA52138A - Procédés d'amélioration de la persistance de lymphocytes t perfusés adoptivement - Google Patents

Procédés d'amélioration de la persistance de lymphocytes t perfusés adoptivement

Info

Publication number
MA52138A
MA52138A MA052138A MA52138A MA52138A MA 52138 A MA52138 A MA 52138A MA 052138 A MA052138 A MA 052138A MA 52138 A MA52138 A MA 52138A MA 52138 A MA52138 A MA 52138A
Authority
MA
Morocco
Prior art keywords
lymphocytes
improvement methods
persistence
adoptively infused
adoptively
Prior art date
Application number
MA052138A
Other languages
English (en)
Inventor
Amir Alpert
Original Assignee
Immatics Us Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Us Inc filed Critical Immatics Us Inc
Publication of MA52138A publication Critical patent/MA52138A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04—Preserving or maintaining viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/505—CD4; CD8
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Developmental Biology & Embryology (AREA)
MA052138A 2018-03-21 2019-03-20 Procédés d'amélioration de la persistance de lymphocytes t perfusés adoptivement MA52138A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862646180P 2018-03-21 2018-03-21
DE102018108612.1A DE102018108612A1 (de) 2018-03-21 2018-04-11 Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen

Publications (1)

Publication Number Publication Date
MA52138A true MA52138A (fr) 2021-01-27

Family

ID=67848236

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052138A MA52138A (fr) 2018-03-21 2019-03-20 Procédés d'amélioration de la persistance de lymphocytes t perfusés adoptivement

Country Status (13)

Country Link
US (2) US20190292520A1 (fr)
EP (1) EP3768330A4 (fr)
JP (1) JP7344898B2 (fr)
KR (1) KR20200133370A (fr)
CN (1) CN112512593A (fr)
AU (1) AU2019240039A1 (fr)
CA (1) CA3094344A1 (fr)
DE (1) DE102018108612A1 (fr)
EA (1) EA202092243A1 (fr)
MA (1) MA52138A (fr)
SG (1) SG11202009082YA (fr)
TW (1) TW202003050A (fr)
WO (1) WO2019183181A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102375218B1 (ko) 2016-12-08 2022-03-17 이매틱스 바이오테크놀로지스 게엠베하 T 세포 수용체 및 이를 사용하는 면역 요법
EA202193139A1 (ru) 2019-05-27 2022-03-01 Имматикс Юс, Инк. Вирусные векторы и их применение в адоптивной клеточной терапии
CA3142386A1 (fr) 2019-06-06 2020-12-10 Immatics Biotechnologies Gmbh Tri avec selection de compteur a l'aide de peptides similaires a une sequence
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
CN110747166B (zh) * 2019-10-11 2021-07-09 厦门大学 一种外周血t细胞的体外扩增培养方法
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
WO2021236548A1 (fr) * 2020-05-18 2021-11-25 Board Of Regents, The University Of Texas System Récepteurs de lymphocytes t modifiés et leurs procédés d'utilisation
TW202227616A (zh) * 2020-08-21 2022-07-16 美商英麥提克斯股份有限公司 分離ｃｄ８＋選擇ｔ細胞的方法
DE102021100038A1 (de) 2020-12-31 2022-06-30 Immatics US, Inc. Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung
MX2023007817A (es) 2020-12-31 2023-09-13 Immatics Us Inc Polipéptidos de cd8, composiciones y métodos de uso de estos.
IL308258A (en) 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh BMA031 antigen-binding polypeptides
KR20230143764A (ko) * 2022-04-06 2023-10-13 주식회사 지씨셀 면역세포에 대한 표적 유전자 도입 방법
US20230348548A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
US20240066127A1 (en) 2022-04-28 2024-02-29 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
WO2023212691A1 (fr) 2022-04-28 2023-11-02 Immatics US, Inc. Polypeptides récepteurs de tgfβ négatifs dominants, polypeptides cd8, cellules, compositions et leurs méthodes d'utilisation
US20230355678A1 (en) 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
WO1997037004A1 (fr) 1996-03-30 1997-10-09 Boehringer Mannheim Gmbh Procede de production de cellules t activees marquees specifiques de tumeurs et leur utilisation pour le traitement de tumeurs
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
WO2001062895A2 (fr) 2000-02-24 2001-08-30 Xcyte Therapies, Inc. Stimulation et concentration simultanees de cellules
CN101437542A (zh) 2006-03-01 2009-05-20 詹森药业有限公司 联合淋巴细胞清除剂与ctl及细胞因子的癌症治疗
US20080131415A1 (en) 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
KR102243575B1 (ko) 2010-12-09 2021-04-22 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도
BR112013018311A2 (pt) 2011-01-18 2017-03-21 Univ Pennsylvania sequência de ácido nucleico isolada, receptor de antígeno quimérico isolado, célula t geneticamente modificada, vetor, e, uso de uma célula t geneticamente modificada.
WO2013126712A1 (fr) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Topicompositions et procédés pour produire une population de lymphocytes t tenaces utiles dans le traitement du cancer
US20150017120A1 (en) 2013-06-13 2015-01-15 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il-2 and adoptive cell therapy
BR112016024957A2 (pt) 2014-04-25 2017-10-24 Bluebird Bio Inc métodos aperfeiçoados para fabricação de terapias celulares adotivas
WO2016022400A1 (fr) 2014-08-04 2016-02-11 Fred Hutchinson Cancer Research Center Immunothérapie par cellules t spécifiques de la wt-1
EP3034092A1 (fr) 2014-12-17 2016-06-22 Université de Lausanne Immunothérapie adoptive pour traiter le cancer
EP3283619B1 (fr) 2015-04-17 2023-04-05 Novartis AG Procédés pour améliorer l'efficacité et l'expansion de cellules exprimant un récepteur antigénique chimérique
WO2017044487A1 (fr) 2015-09-09 2017-03-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Modification génétique de macrophages pour l'immunothérapie
GB201604458D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers

Also Published As

Publication number Publication date
SG11202009082YA (en) 2020-10-29
TW202003050A (zh) 2020-01-16
US20190292520A1 (en) 2019-09-26
AU2019240039A1 (en) 2020-11-12
EP3768330A1 (fr) 2021-01-27
US20210017493A1 (en) 2021-01-21
CN112512593A (zh) 2021-03-16
EA202092243A1 (ru) 2021-01-29
JP2021518121A (ja) 2021-08-02
US11905529B2 (en) 2024-02-20
JP7344898B2 (ja) 2023-09-14
EP3768330A4 (fr) 2021-05-19
KR20200133370A (ko) 2020-11-27
CA3094344A1 (fr) 2019-09-26
DE102018108612A1 (de) 2019-09-26
WO2019183181A1 (fr) 2019-09-26

Similar Documents

Publication Publication Date Title
MA52138A (fr) Procédés d'amélioration de la persistance de lymphocytes t perfusés adoptivement
FR23C1043I1 (fr) Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t
MA53822A (fr) Protéines de fusion fc hétérodimères d'il -12
FR23C1015I1 (fr) Procédés de sélection d'une lignée de lymphocytes t et donneur de lignée de lymphocytes t pour thérapie cellulaire adoptive
EP3813682A4 (fr) Systèmes médicaux incorporant un partage de poulie
SG11202109267UA (en) Blood flow rate measurement system
MA41463A (fr) Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
MA50948A (fr) Anticorps et procédés d'utilisation de ceux-ci
EA201790425A1 (ru) Новые соединения спиро[3h-индол-3,2'-пирролидин]-2(1h)-она и производные в качестве ингибиторов mdm2-p53
MA40894A (fr) Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
MA40721A (fr) Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
MA50045A (fr) Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci
MA47246A (fr) Cabine de peinture dotée d'un système de filtre automatique
MA46059A (fr) Variants de l'endonucléase homing tim3, compositions et procédés d'utilisation
MA39248B1 (fr) Anticorps anti-jagged1 et procédés d'utilisation correspondants
EP3887402A4 (fr) Plaquettes utilisées comme agents d'administration
MA50041A (fr) Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci
EP3790461A4 (fr) Systèmes de canule de détection
EP3785014A4 (fr) Méthodes de diagnostic d'une maladie par cytométrie en microflux
MA55911A (fr) Lymphocytes t génétiquement modifiés
EP3863609A4 (fr) Petits supports polymériques pour l'administration d'agents
EP3893740A4 (fr) Système de restriction de flux sanguin
MA55010A (fr) Système d'électrodes
EP3877749A4 (fr) Système optique et cytomètre en flux
FR3040828B1 (fr) Systeme de mesure de duree ou de profil temporel d'impulsion laser ultrabreve